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Background: Increased lipid accumulation and mitochondrial dysfunction within skeletal muscle have been shown
to be strongly associated with insulin resistance. However, the role of mitofusion-2 (MFN2), a key factor in
mitochondrial function and energy metabolism, in skeletal muscle lipid intermediate accumulation remains to
be elucidated.
Results: A high-fat diet resulted in insulin resistance as well as accumulation of cytosolic lipid intermediates and
down-regulation of MFN2 and CPT1 in skeletal muscle in rats, while MFN2 overexpression improved insulin
sensitivity and reduced lipid intermediates in muscle, possibly by upregulation of CPT1 expression.
Conclusions: MFN2 overexpression can rescue insulin resistance, possibly by upregulating CPT1 expression leading
to reduction in the accumulation of lipid intermediates in skeletal muscle. These observations contribute to the
investigations of new diabetes therapies.
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Type 2 diabetes is characterized by insulin resistance
(which affects skeletal muscle, liver and other insulin-
sensitive tissues) and by defective insulin secretion [1]. In-
creased adiposity and lipid accumulation within the skel-
etal muscle and mitochondrial dysfunction have been
shown to be strongly associated with insulin resistance [2].
Important studies have appeared in recent years to
reinforce the view that it is active lipid intermediates such
as long-chain fatty acid CoAs (LCCoAs), diacylglycerols
(DAG) and ceramides (CEA) that result in lipid-induced
muscle insulin resistance [3,4].
Skeletal muscle is quantitatively the major contributor
to whole body insulin-mediated glucose disposal. Fat accu-
mulation in muscle negatively impacts insulin-mediated
glucose uptake. The hypothesis that insulin resistance is
related to lipid accumulation in muscle dates back to stud-
ies reported 15–20 years ago showing that triglycerides ac-
cumulate in muscle in rats fed a high-fat diet, which is* Correspondence: sguangyao2@163.com
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reproduction in any medium, provided the orcoincident with insulin resistance. Since then the rele-
vance of muscle lipid accumulation to insulin resistance in
humans has been demonstrated, and basic studies have in-
dicated plausible mechanisms whereby lipid accumulation
could generate insulin resistance [5].
There may be multiple metabolic causes for increased
cytosolic lipid accumulation in muscle in insulin-
resistant states. Theoretically, a decrease in fatty acid β-
oxidation can lead to lipid accumulation. The acceler-
ation of fatty acid β-oxidation may lessen the potential
for insulin resistance [6,7].
CPT1 is the rate-limiting enzyme that controls the
transfer of cytosolic LCCoAs into mitochondria for oxida-
tion. Slight increases in CPT1 expression in muscle can
direct lipids away from storage and into oxidation, at least
in rodents, indicating the importance of this regulatory
step in opposing cytosolic lipid accumulation [8]. Mito-
chondrial dysfunction has been reported in skeletal muscle
in type 2 diabetic patients [9-11]. There is evidence that
insulin-resistant obese individuals with type 2 diabetes
have approximately 30% fewer mitochondria in their skel-
etal muscle than age-matched healthy controls [12]. It isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2 diabetes.
Mitofusin-2 (MFN2) protein is a dynamin-related pro-
tein with GTPase activity anchored in the external mito-
chondrial membrane [13]. MFN2 is abundantly expressed
in skeletal muscle [14-16] and its activity is crucial in the
maintenance of mitochondrial tubules in cultured muscle
cells [17]. Overexpression of MFN2 in HeLa cells causes
perinuclear aggregation of mitochondria, a marked en-
hancement of mitochondrial membrane potential and in-
creased glucose oxidation [17]. Detection of mitochondrial
function includes measures of fatty acid oxidation and oxi-
dative phosphorylation. Indicators of fatty acid oxidation
potential include measurements of enzymes associated
with fatty acid transport protein into the cell (fatty acid
transport protein (CD36) [18], fatty acid transport into the
mitochondria (carnitine palmitoyltransferase I [CPT1]
[19], and fatty acid β-oxidation (β-hydroxyacyl-CoA de-
hydrogenase [HADH] [20].
Previous studies confirmed that high-fat diets induced in-
sulin resistance and MFN2 down-regulation in rat muscle
[21] (David Sebastián, et al. 2012). However, the roles of
MFN2, a key factor for mitochondria function and energy
metabolism, in skeletal muscle lipid intermediate accumula-
tion remain to be elucidated.
In this study, we established a model of insulin resist-
ance in rats by provision of a high-fat diet. Furthermore,
an MFN2-expressing adenovirus was used to investigate
the mechanism by which MFN2 relieves skeletal muscle




The animal experiments were conducted according to pro-
tocols reviewed and approved by the Animal Experimental
Ethics Committee of Hebei General Hospital, Shijiazhuang,
China (approval ID: HBGH-2010027). Four-week-old male
Sprague Dawley (SD) rats (70 ± 10 g) were housed indi-
vidually at 22°C, in 12 h/12 h light/dark conditions and
50% relative humidity. SD rats were divided randomly into
two groups of 36: normal diet (8 N) group (n = 12), high-
fat diet (8 F) group (n = 24). The 8 N group was fed with a
standard carbohydrate diet (10.3% fat, 24.2% protein, and
65.5% carbohydrate), while the 8 F group was fed with
a high-fat diet (59.8% fat, 20.1% protein, and 20.1%Table 1 Primer sequences for quantitative PCR
Gene Forward primer (5'-3') Reverse primer (5'-3')
β-actin CGGTCAGGTCATCACTATCG GAAGGAAGGCTGGAAGAGAG
MFN2 AGCGTCCTCTCCCTCTGACA TTCCACACCACTCCTCCGAC
CPT1 CCAGGCAAAGAGACAGACTTG GCCAAACC TTAGAGAAGCGA
CD36 AATGAGACTGGGACCATCG CTCCAACACCAAGTAAGACCATcarbohydrate). After 8 weeks of feeding, insulin resistance
in each group was evaluated by glucose infusion rate (GIR)
using the hyperinsulinemic euglycemic clamp technique in
the conscious state. Six randomly selected rats in each
group were then sacrificed by exsanguination. Fasting
blood glucose (BG) levels were measured using an Accu-
chek Active Meter (ACCU-CHEK® Active; Roche,Basel,
Switzerland), Fasting serum insulin levels were determined
with a rat insulin ELISA kit (Crystal Chem. Inc.). SkeletalFigure 1 High-fat diets resulted in insulin resistance in rats. Rats
were fed with high-fat diets or normal diets for 8 weeks, when the
levels of blood glucose (A) and plasma insulin (B) were measured.
The GIR, assayed by hyperinsulinemic euglycemic clamping, was
used to assess insulin sensitivity in rats (C). **P < 0.01, compared
with normal diets (8 N), n = 6.
Figure 2 High-fat diets resulted in lipid accumulation in skeletal muscle. Rats were fed with high-fat diet or normal diet for 8 weeks, when
the levels of TG (A), LCCoAs (B), DAG (C), CER (D) were measured. **P <0.01, compared with normal diet (8 N), n = 6.
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quid nitrogen and stored at −80°C. The high-fat diet (8 F)
group was divided randomly into three groups: high-fat
diet control (control) group, empty adenovirus (Ad) group,
and MFN2 overexpression (Ad-MFN2) group. All rats
were then infected with PBS as a control, empty adeno-
virus or the MFN2 overexpressing adenovirus (109 v.p./kg
body weight) once a week for 3 weeks. The MFN2
overexpressing adenovirus (Ad-MFN2) and the empty
control adenovirus (Ad) were obtained from Dr Rui
Zhang, Hebei Medical University [22]. Except for the pe-
riods of pretest overnight fasting and the immediate post-
operative period, animals had free access to water and
chow. Hyperinsulinemic clamp studies were repeated to
confirm the amelioration of insulin resistance. Overnight-
fasted rats were anesthetized with sodium pentobarbital
(3% Pelltobarbitalum Natricum, 60 mg/kg, intraperitone-
ally) and blood samples were obtained from the abdominal
aorta. Skeletal muscle tissue was immediately removed,
freeze-clamped in liquid nitrogen and stored at −80°C.
Hyperinsulinemic euglycemic clamp
Insulin sensitivity can be measured using a variety of tech-
niques that are commonly employed in diabetes research
and care. Of these, the hyperinsulinemic euglycemic clamp
is the gold-standard method. Hyperinsulinemic clamp
studies were performed as previously described [23]. Rats
were placed under general anesthesia (3% Pelltobarbitalum
Natricum, 60 mg/kg, intraperitoneally) and catheters were
inserted into the right jugular vein and the carotid arteriesof rats and exteriorized from the back of the neck sub-
cutaneously. At the end, the catheters were flushed with iso-
tonic saline containing heparin (50 units/ml). Rats were
allowed a minimum of 3 days for full recovery and only those
that had lost less than 5% of their preoperative weights were
used in experiments. Euglycemic-hyperinsulinemic clamps
were performed on fasted, awake, and unrestrained animals.
Insulin (4 mU/kg/min) was infused through the jugular vein
catheter from 0 to 90 min. Glucose concentrations were
clamped at euglycemic levels by a variable rate infusion of
30% glucose. BG levels were monitored with a glucometer
(ACCU-CHEK® Active; Roche), and GIR were adjusted every
5–10 min as required. A stable GIR was obtained within ap-
proximately 60 minutes of the insulin infusion and
maintained thereafter. At steady state, mean GIR was nor-
malized to body weight.
Electron microscopy
Skeletal muscle samples to be used for electron micros-
copy were cut into small pieces (1 × 1 × 2 mm) and fixed
in 2.5% glutaraldehyde, post-fixed in 1% osmium tetrox-
ide, dehydrated, and embedded in Epon in the longitu-
dinal orientation. After an initial low-power screening of
semithin (300 nm) sections stained with toluidine blue
to optimize the plane of sectioning, ultrathin (60 nm)
longitudinal sections were cut for each sample. The sec-
tions were mounted on copper grids and stained with
lead citrate and uranyl acetate. For each biopsy, at least
10 longitudinal sections were examined by transmission
electron microscopy (TEM) (H-7500, Japanese Hitachi
Figure 3 High-fat diets inhibited MFN2 and CPT1 in rat skeletal
muscle. Rats were fed with high-fat diet (8 F) or normal diet (8 N)
for 8 weeks, when the expression levels of MFN2, CPT1 and CD36
were assayed by quantitative RT-PCR (A) and Western blot (B, C).
*P < 0.05, **P < 0.01, compared with normal diets (8 N), n = 6.
Figure 4 Representative transmission electron micrographs
(original magnification: ×15,000) of skeletal muscle from a
normal diet rat (A), a high-fat diet rat (B), and MFN2
overexpressing adenovirus infected (109 v.p./kg body weight)
rat (C). Several mitochondria are labeled with the letter M. Z-lines
are labeled with the letter Z.
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10 micrographs were taken at 15,000 ×magnification.Determination of skeletal muscle triglycerides, long-chain
fatty acid CoAs, diacylglycerol and ceramides
Triacylglycerols were extracted with a 2:1 chloroform-
methanol solution and quantified with an enzymaticassay kit (Wako Pure Chemical Industries) as previously
described [6]. Extraction of long-chain fatty acid CoAs,
diacylglycerol and ceramides via HPLC was performed
as previously described [24,25].Real-time RT-PCR
Total RNA was extracted from frozen skeletal muscle
using a standard TRIzol (Invitrogen, USA) RNA isolation
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according to the instructions of the Easy Script First-
Strand cDNA Synthesis Super Mix kit (Trans Gen Bio-
tech, CA). Specific primers designed for amplification of
MFN2, CPT1, CD36 and β-actin were verified by NCBI
Blast; primers sequences are shown in Table 1. Real-time
PCR was performed on an ABI PRISM 7300 PCR System
(Applied Bio systems, USA) using SYBR Green I GoTaq®
qPCR Master Mix (Promega, USA). PCRs were carried
out in a total of 25 μl as follows: one cycle at 95°C for
5 min, followed by 40 cycles of 95°C for 15 s, 58°C for 20 s
and 72°C for 30 s. The gene expression from each sample
was analysed in duplicates and normalized against β-actin.
The results are expressed as relative gene expression using
the ΔCt method.
Western blot analysis
Frozen skeletal muscle was prepared with lysis buffer
(1% Triton X-100, 150 mM NaCl, 10 mM Tris–HCl
(pH 7.4); 1 mM EDTA, 1 mM EGTA (pH 8.0); 0.2 mM
Na3VO4, 0.2 mM phenylmethylsulfonyl fluoride, and
0.5% NP-40). Equal amounts of proteins were separatedFigure 5 MFN2 overexpression improved insulin sensitivity in rats. Ra
with Ad-Mfn2 (109 v.p./kg body weight) or empty Ad adenoviruses or PBS
was confirmed by quantitative RT-PCR (A) and Western blot analyses (B, C)
sensitivity (F) were assayed. *P < 0.05, **P < 0.01, compared with Ad, n = 6.by 10% SDS-PAGE, and electrotransferred to PVDF
membranes (Millipore, USA), and then were blocked
with 5% BSA for 2 h at room temperature. Membranes
were incubated with appropriately diluted rabbit anti-rat
primary antibodies for detection of MFN2 (Bioworld
Technology, Inc.), CPT1 (Santa Cruz), CD36 (Santa Cruz)
or mouse anti-rat β-actin (Cell Signaling Technology)
overnight at 4°C. Membranes were then incubated with
the relevant secondary antibodies (MFN2, CD36, CPT1:
anti-rabbit IgG; β-actin: anti-mouse IgG; all from Santa
Cruz) for 2 h at 20°C. Proteins were detected with the
enhanced chemiluminescence (ECL) detection system.
β-actin was served as an internal control protein.
Statistical analysis
All experiments were repeated at least three times.
Values are represented as means ± SD. All statistical ana-
lyses were performed with the SPSS statistical package
(SPSS 16.0 software). Statistical significance was assessed
by ANOVA (post-hoc used Student-Newman-Keuls test)
and unpaired Student’s t-tests (P-values < 0.05 were con-
sidered significant).ts were fed with high-fat diets for 8 weeks, and then were infected
control for 3 weeks. MFN2 overexpression in skeletal muscle of rats
. The levels of blood glucose (D), plasma insulin (E) and insulin
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Evaluation of insulin sensitivity in high-fat diet
treated rats
Fasting plasma glucose levels, serum insulin levels and
glucose infusion rates (GIR) in rats are presented as
Figure 1. Compared with rats fed a normal diet, high-fat
diet rats exhibited obviously impaired insulin sensitivity,
indicated by increased levels of fasting plasma glucose
(7.2 ± 0.6 mmol/l vs. 5.7 ± 0.7, P < 0.01 mmol/l) and fasting
serum insulin (40.6 ± 3.9 mU/l vs. 28.7 ± 3.3 mU/l, P <
0.01). Compared with control rats, GIR decreased mark-
edly in high-fat diet rats (17.7 ± 2.3 mg/kg/min vs. 29.4 ±
2.4 mg/kg/min, P < 0.01).High-fat diet increased the accumulation of lipid
intermediates in skeletal muscle, and downregulated the
expression of MFN2 and CPT1
As shown in Figure 2, compared with control rats, the
levels of lipid intermediates in skeletal muscle of high-fat
diet rats were significantly increased (LCCoAs 6.0 ±
0.8 nmol/g vs. 2.2 ± 0.3 nmol/g, DAG 563.0 ± 48.3 nmol/g
vs. 211.5 ± 31 nmol/g, CEA 130.3 ± 9.3 nmol/g vs. 67.2 ±
12.2, P < 0.01 nmol/g). We also observed a high-fat diet-
induced decrease in the expression of MFN2 at both the
mRNA and protein levels (Figure 3). The expression of
CPT1 was concomitantly decreased significantly (P < 0.01)Figure 6 MFN2 overexpression lowered lipid intermediate accumulat
TG accumulation. Rats were fed with high-fat diets for 8 weeks, and then
adenoviruses or PBS control for 3 weeks. The levels of TG (A), LCCoAs (B), D
with Ad, n = 6.(Figure 3), while the expression of CD36 was increased
markedly (P < 0.01) (Figure 3).Changes in mitochondrial morphology following MFN2
overexpression
The effect of MFN2 on the mitochondrial morphology
in skeletal muscle was investigated by electron micros-
copy. This method allows accurate assessment of ultra-
structural morphology as well as the number of
mitochondria and cristae. As shown in the representative
photographs in Figure 4, mitochondria from muscle in the
MFN2 overexpression group exhibited a more clearly de-
fined internal membrane structure, including wider cristae,
compared with those observed in the high-fat diet group.Overexpression of MFN2 ameliorated insulin resistance
induced by a high-fat diet in rats
n order to investigate the effect of MFN2 on insulin sensi-
tivity, rats were fed a high-fat diet for 8 weeks and then
infected with Ad-MFN2 or empty Ad adenoviruses or
PBS control for 3 weeks. MFN2 expression in rat muscle
was increased dramatically by Ad-MFN2 infection
(Figure 5A,B and C). At the same time, fasting BG (Con-
trol: 7.18 ± 0.6 mmol/l; Ad: 7.2 ± 0.7 mmol/l; Ad-Mfn2: 5.9
± 0.7 mmol/l, Figure 5D) and plasma insulin levels de-
creased (Control: 40.0 ± 5.9 mU/l; Ad: 40.1 ± 5.9 mU/l; Ad-ion in rat skeletal muscle, but had no significant effect on muscle
were infected with Ad-Mfn2 (109 v.p./kg body weight) or empty Ad
AG (C) and CER (D) were measured. *P < 0.05, **P <0.01, compared
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(Control: 17.74 ± 2.34 mg/kg/min; Ad: 17.91 ± 2.56 mg/kg/
min; Ad-Mfn2: 28.16 ± 4.71 mg/kg/min, Figure 5F) mark-
edly with Ad-Mfn2 infection. The results indicated that
MFN2 overexpression neutralized the effects of a high-fat
diet on insulin sensitivity.
Overexpression of MFN2 improved accumulation of
muscle lipid intermediates in high-fat diet rats
Changes in lipid intermediate accumulation in rat muscle
overexpressing MFN2 were detected by HPLC assays. Al-
though there were no significant changes in the accumula-
tion of TG (Figure 6A), the accumulation of lipid
intermediates, such as LCCoAs, DAG and CER was mark-
edly reduced (Figure 6B, C and D). These changes were
concomitant with improved insulin sensitivity.
Overexpression of MFN2 increased CPT1 expression
As shown in Figure 7, CPT1 was upregulated markedly
at both the mRNA and protein levels (Figure 7D, E and
F), while the expression of CD36 was not significantlyFigure 7 MFN2 overexpression increased CPT1 mRNA and protein ex
muscle CD36 expression. Rats were fed with high-fat diets for 8 weeks, a
empty Ad adenoviruses or PBS control for 3 weeks. The expression levels o
and Western blot. *P < 0.05, **P < 0.01, compared with Ad, n = 6.affected (Figure 7A, B and C). The results suggested that
MFN2 improvement of insulin sensitivity may be corre-
lated with decreased lipid accumulation.
Discussion
Our study suggested that MFN2 expression and insulin
sensitivity were inhibited by a high-fat diet, with concomi-
tant accumulation of lipid intermediates in the muscle.
This is in agreement with previously reported findings
[21]. Furthermore, we demonstrated that overexpression
of MFN2 recovered insulin sensitivity and reduced lipid
accumulation, which may be associated with CPT1
upregulation in skeletal muscle.
Over-consumption of fat is a significant contributor to
the development of obesity and insulin resistance. High-
fat-diets enriched with lard were widely used to induce
an obese animal model of insulin resistance [26]. In this
study, lipid accumulation in skeletal muscle was ob-
served in rats fed a high-fat diet, while MFN2 and CPT1
expression was downregulated dramatically and CD36
expression was increased. This may suggest that thepression in rat skeletal muscle, but had no significant effects on
nd then were infected with Ad-MFN2 (109 v.p./kg body weight) or
f CD36 (A, B, C) and CPT1 (D, E, F) were measured by Real-time PCR
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of mitochondrial dysfunction, while the higher expres-
sion of CD36 is compensational for increased blood
plasma free fatty acid levels induced by a high-fat diet.
When the levels of fatty acids transported into the cyto-
sol exceed the capacity for mitochondrial oxidation, lipid
or lipid intermediates are deposited in skeletal muscle.
Normally, the binding of insulin to insulin receptors
stimulates autophosphorylation of tyrosine residues and
subsequent activation of a receptor tyrosine kinase. This
tyrosine kinase phosphorylates multiple intracellular sub-
strates, including insulin receptor substrate (IRS) 1 and 2,
which play significant roles in the insulin response. This is
mediated by IRS activation of phosphatidylinositol 3-
kinase (PI 3-kinase), a critical player in insulin signaling
particularly with regard to glucose homeostasis. Phos-
phatidylinositol 3-kinase facilitates the translocation of the
insulin-responsive glucose transporter (GLUT4) to the
plasma membrane through a mechanism that is thought
to be mediated by phosphorylation [27]. Recent studies
confirm that lipid intermediates such as long-chain fatty
acid CoA species (LCCoAs), diacylglycerol (DAG), and
ceramides (CEA) disrupt one or more of the early steps in
insulin signal transduction. These compounds have been
implicated in the activation of isoforms of PKC, leading to
impairment of phosphatidylinositol 3-kinase (PI3K) activ-
ity and inhibition of the activation of PKB (Akt/PKB) as
well as decreased insulin-induced glucose transportation
and glycogen synthesis [28].
Mitochondria are the primary cellular sites for fatty acid
oxidation and utilization. Mitochondrial dysfunction plays
an important role in the development of insulin resistance
in skeletal muscle [29]. MFN2 is a proliferation-inhibiting
gene encoding a mitochondrial fusion protein that partici-
pates in the maintenance of mitochondrial morphology
and regulates mitochondrial metabolism and intracellular
signaling [16,30]. Although the central role of MFN2 in
mitochondrial metabolism is well-established [29], its roles
in insulin resistance in skeletal muscle and muscle lipid
intermediate accumulation remain uncertain.
Mitochondrial β-oxidation represents a crucial process in
energy metabolism and is tightly regulated by interactions
between the key enzymes carnitine palmitoyltransferase 1
(CPT1) and acetyl-CoA carboxylase (ACC) via the inter-
mediate malonyl-CoA. CPT1 is an integral membrane
protein that associates with the mitochondrial outer
membrane through transmembrane regions in the peptide
chain. Both MFN2 and CPT1 are regulated by peroxisome
proliferators-activated receptor coactivator-1 (PGC1). CD36
is a multifunctional membrane-associated glycoprotein with
a molecular weight of 88 kDa. It plays an important role in
the uptake of long-chain fatty acids (LCFAs) in skeletal
muscle [31]. Superficially, there are no direct association be-
tween CPT1 and CD36; however, more recent informationsuggests that CPT1 may not act alone in the regulation of
fatty acyl-CoA entry into the mitochondria. Recent studies
have demonstrated that the fatty acid translocase FAT/
CD36 is present on the mitochondrial membrane of both
rodent and human skeletal muscle, where it plays an im-
portant role in regulating fatty acid oxidation [32]. Above
all, the elucidation of the highly complex relationships
among MFN2, CPT1 and CD36 are of critical significance.
In the current study, our data demonstrate that over-
expression of MFN2 significantly restored insulin sensitivity
and reduced the levels of BG and plasma insulin in rats,
suggesting MFN2 as a potential therapeutic target in insulin
resistance. It can be speculated that the mechanism under-
lying the improvement in insulin resistance associated with
MFN2 overexpression is mediated by improved mitochon-
drial function. Consequently, with the upregulation of
CPT1, the redundant lipid intermediates in the cytosolic
were transported into the mitochondria for β-oxidation,
thus relieving the damage to insulin signaling resulting
from the accumulated lipid intermediates.
Conclusion
In conclusion, our data suggest that MFN2 ameliorates
insulin resistance induced by a high-fat diet through
upregulation of CPT1, which relieves lipid intermediates
accumulation in skeletal muscle. Therefore MFN2 is im-
plicated as a potential target for the treatment of insulin
resistance and metabolic syndromes.
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